Study types
- article 73
- other 9
- review 3
- rct 2
- dataset 1
Condition tags
- endometriosis 88
- dysmenorrhea 20
- dyspareunia 18
- chronic_pelvic_pain 18
- infertility 7
- irritable_bowel_syndrome 1
- interstitial_cystitis 1
Top journals
Frequent coauthors
OBJECTIVE: This study sought to estimate the prevalence of diagnosis of endometriosis (DxE) in Canada and to assess the symptomatic and diagnostic experience of Canadian women with DxE. METHOD: A cross-sectional, online survey of women in C…
BACKGROUND: Endometriosis is a common problem in women of reproductive age and has impacts on health-related quality of life and productivity. Fatigue is an important part of the burden of endometriosis, it is not often included as an endpo…
STUDY OBJECTIVE: To determine the prevalence and pattern of opioid use in endometriosis and the characteristics of patients prescribed an opioid using medical insurance claims data. DESIGN: We performed a retrospective cohort analysis of da…
OBJECTIVES: Evaluate all-cause and endometriosis-related health care resource utilization and costs among newly diagnosed endometriosis patients with high-risk versus low-risk opioid use or patients with chronic versus non-chronic opioid us…
Introduction: We aimed to characterize the treatment patterns of women with a self-reported diagnosis of endometriosis in Canada. Methods: Between December 2018 and January 2019 an online cross-sectional survey was administered to women age…
Background: The daily pain burden experienced by women with endometriosis has not been well studied. Objective: To characterize baseline pain among women with moderate-to-severe endometriosis-associated pain enrolled in phase 3 studies of e…
AIM: To assess the cost-effectiveness of elagolix versus leuprolide acetate in women with moderate to severe endometriosis pain. METHODS: A Markov model was developed. The efficacy of leuprolide acetate was derived from statistical predicti…
Objectives: The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain. Methods: Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies …
Aims: Opioids do not represent standard therapy for endometriosis; however, women with endometriosis are frequently prescribed an opioid to manage related abdominal or pelvic pain. The aim of this study was to evaluate the impact of opioid …
BACKGROUND: Endometriosis is a painful chronic inflammatory disease caused by endometrial tissue implanting and growing outside the uterus, resulting in pelvic pain symptoms and subfertility. Treatment imposes a substantial economic burden …
ObjectiveTo estimate the impact of elagolix on work loss due to endometriosis-associated pain.DesignPost hoc analysis of data from the Elaris I and II clinical trials.SettingNot applicable.Patient(s)Employed women ages 18–49 years with mode…
BACKGROUND: Endometriosis profoundly impairs women's workplace and household productivity. OBJECTIVE: The aim of this study was to evaluate the impact of elagolix on endometriosis-related workplace and household productivity losses. METHODS…
OBJECTIVE: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. DESIGN: Randomized, double-blind, multicenter, placebo-controlled phase …
INTRODUCTION: Despite guidance towards minimally invasive, outpatient procedures for endometriosis, many patients nonetheless receive inpatient care. Our objective was to assess trends in patient and hospital characteristics, surgical compl…
OBJECTIVE: To examine opioid use, opioid prescribing patterns, and timing of the first opioid prescription in endometriosis patients compared with matched women in the control group without endometriosis. METHODS: We conducted a retrospecti…
(Abstracted from Obstet Gynecol 2019;133:1120–1130) Misuse and abuse of prescription opioids has increased dramatically in recent years and is reported to be the fastest-growing drug problem in the United States. Of the more than 350,000 de…